Why EyePoint Stock Is Back On Investors’ Radar

EyePoint (EYPT) has drawn fresh attention after a sharp daily move, with the stock down 6.7% at the last close of US$12.35, extending declines over the past week and month.

The recent 1-day share price decline of 6.7% extends a weak near term trend, with the stock down 9.6% over the past week and 16.6% over the past month. However, the 1-year total shareholder return of 101.5% shows longer term investors are still sitting on strong gains.

If EyePoint’s swings have you looking beyond a single stock, this is a good moment to broaden your watchlist with 32 healthcare AI stocks

With EyePoint shares well below the analyst price target of US$37 and trading at what some might see as an intrinsic discount of about 86%, you have to ask: is this a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 66.8% Undervalued

With EyePoint last closing at $12.35 against a narrative fair value of $37.17, the current discount is large enough that the underlying thesis deserves a closer look.

Analysts are assuming EyePoint's revenue will grow by 102.6% annually over the next 3 years. Analysts are not forecasting that EyePoint will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate EyePoint's profit margin will increase from 739.4% below breakeven to the average AU Pharmaceuticals industry of 18.9% in 3 years.

Want to see how fast revenue growth, a big profit margin swing and a premium future earnings multiple tie together into that fair value? The full narrative lays out the step by step blueprint behind those assumptions and how they connect to the analyst price target.

Result: Fair Value of $37.17 (UNDERVALUED)

However, the story can change quickly if DURAVYU stumbles in late stage trials or approval, or if heavier spending and ongoing losses force fresh fundraising.

Next Steps

With sentiment clearly split between the potential upside and the clear risks, it can be helpful to act promptly and review the details yourself. To see both sides of the story in one place, review the 2 key rewards and 3 important warning signs

Looking for more investment ideas?

Do not stop with a single stock story. Broaden your opportunity set now with focused stock lists built from clear fundamentals and transparent data.

• Target potential mispricings by scanning 50 high quality undervalued stocks that combine solid business quality with what some investors may view as discounted share prices.
• Strengthen portfolio resilience by reviewing the 66 resilient stocks with low risk scores built around companies with lower risk scores and steadier financial profiles.
• Get ahead of the crowd by checking the screener containing 22 high quality undiscovered gems where strong fundamentals meet lower market attention and limited coverage.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.